+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

PARP Inhibitors Drug Therapy Market by Drug, Indication, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 187 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 5674431
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The PARP Inhibitors Drug Therapy Market grew from USD 6.73 billion in 2023 to USD 7.32 billion in 2024. It is expected to continue growing at a CAGR of 9.15%, reaching USD 12.43 billion by 2030.

PARP inhibitors are a class of drugs designed to impede the enzyme poly ADP-ribose polymerase (PARP), primarily used in the treatment of various cancers, including ovarian, breast, and prostate cancers. These drugs have become essential due to their ability to exploit the inherent weaknesses in cancer cells, particularly those with BRCA1/2 mutations, offering a targeted therapeutic approach leading to cell death. Their application is primarily prevalent in oncology, but recent studies suggest potential across other domains, expanding their end-use scope. The market for PARP inhibitors is currently experiencing vigorous growth, fueled by increased research investments, an aging population, and rising cancer prevalence. Key growth factors include advances in personalized medicine and a burgeoning pipeline of PARP-related therapies. Emerging opportunities lie in exploring combinatory approaches with other anti-cancer drugs and expanding indications beyond traditional cancers.

However, the market is fraught with challenges such as high drug development costs, stringent regulatory environments, and the development of resistance in some patients, limiting the efficacy of PARP inhibitors over time. Additionally, the competitive landscape is intensifying with numerous pharmaceutical companies investing heavily in R&D activities. Limiting factors also include the accessibility of these drugs in emerging markets due to cost constraints. Despite these challenges, areas ripe for innovation include developing next-generation PARP inhibitors capable of overcoming resistance and enhancing bioavailability. Additionally, leveraging advanced technologies like artificial intelligence to expedite drug discovery and employing real-world evidence in clinical trials can significantly optimize development timelines and therapeutic outcomes.

For market players, focusing on strategic partnerships, mergers, and acquisitions could facilitate market penetration and expansion. Moreover, prioritizing patient education on the benefits of PARP inhibitors can accelerate market uptake, especially in underserved regions. The PARP inhibitors market exhibits a promising growth trajectory but requires vigilance in overcoming barriers to truly unleash its potential.

Understanding Market Dynamics in the PARP Inhibitors Drug Therapy Market

The PARP Inhibitors Drug Therapy Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Increasing prevalence of cancers
    • Growing numbers of clinical trials worldwide
    • Elevation in government approvals for PARP drugs
  • Market Restraints
    • High cost of treatment
  • Market Opportunities
    • Ongoing research and development projects to introduce novel drug therapies
    • Governmental programs to enhance the cancer treatment therapies
  • Market Challenges
    • Concerns associated with side effects of drug therapy

Exploring Porter’s Five Forces for the PARP Inhibitors Drug Therapy Market

Porter’s Five Forces framework further strengthens the insights of the PARP Inhibitors Drug Therapy Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the PARP Inhibitors Drug Therapy Market

External macro-environmental factors deeply influence the performance of the PARP Inhibitors Drug Therapy Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the PARP Inhibitors Drug Therapy Market

The PARP Inhibitors Drug Therapy Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the PARP Inhibitors Drug Therapy Market

The PARP Inhibitors Drug Therapy Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the PARP Inhibitors Drug Therapy Market

The PARP Inhibitors Drug Therapy Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the PARP Inhibitors Drug Therapy Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Artios Pharma Limited, AstraZeneca PLC, BeiGene, Inc., Bristol-Myers Squibb Company, Clovis Oncology, GlaxoSmithKline PLC, IMPACT Therapeutics, Jeil Pharmaceuticals Co. Ltd., Jiangsu Hengrui Pharmaceuticals Company Ltd., Johnson & Johnson Services, Inc., Karyopharm Therapeutics, Merck & Co., Inc., Ono Pharmaceutical Co., Ltd., Pfizer Inc., and Repare Therapeutics, Inc..

Market Segmentation & Coverage

This research report categorizes the PARP Inhibitors Drug Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Drug
    • Niraparib
    • Olaparib
    • Rucaparib
    • Talazoparib
  • Indication
    • Breast Cancer
    • Ovarian Cancer
    • Pancreatic Cancer
    • Prostate Cancer
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of cancers
5.1.1.2. Growing numbers of clinical trials worldwide
5.1.1.3. Elevation in government approvals for PARP drugs
5.1.2. Restraints
5.1.2.1. High cost of treatment
5.1.3. Opportunities
5.1.3.1. Ongoing research and development projects to introduce novel drug therapies
5.1.3.2. Governmental programs to enhance the cancer treatment therapies
5.1.4. Challenges
5.1.4.1. Concerns associated with side effects of drug therapy
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. PARP Inhibitors Drug Therapy Market, by Drug
6.1. Introduction
6.2. Niraparib
6.3. Olaparib
6.4. Rucaparib
6.5. Talazoparib
7. PARP Inhibitors Drug Therapy Market, by Indication
7.1. Introduction
7.2. Breast Cancer
7.3. Ovarian Cancer
7.4. Pancreatic Cancer
7.5. Prostate Cancer
8. PARP Inhibitors Drug Therapy Market, by Distribution Channel
8.1. Introduction
8.2. Hospital Pharmacies
8.3. Online Pharmacies
8.4. Retail Pharmacies
9. Americas PARP Inhibitors Drug Therapy Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific PARP Inhibitors Drug Therapy Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa PARP Inhibitors Drug Therapy Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. PARP INHIBITORS DRUG THERAPY MARKET RESEARCH PROCESS
FIGURE 2. PARP INHIBITORS DRUG THERAPY MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
FIGURE 7. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 9. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 11. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 13. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 15. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. PARP INHIBITORS DRUG THERAPY MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 21. PARP INHIBITORS DRUG THERAPY MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. PARP INHIBITORS DRUG THERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. PARP INHIBITORS DRUG THERAPY MARKET DYNAMICS
TABLE 7. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY NIRAPARIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OLAPARIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RUCAPARIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TALAZOPARIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 22. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 23. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 24. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 25. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 26. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 27. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 28. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 29. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 30. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 31. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 32. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 33. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 34. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 35. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 36. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 37. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 38. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 39. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 40. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 41. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 42. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 43. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 44. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 45. AUSTRALIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 46. AUSTRALIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 47. AUSTRALIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 48. CHINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 49. CHINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 50. CHINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 51. INDIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 52. INDIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 53. INDIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 54. INDONESIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 55. INDONESIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 56. INDONESIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 57. JAPAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 58. JAPAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 59. JAPAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 60. MALAYSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 61. MALAYSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 62. MALAYSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 63. PHILIPPINES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 64. PHILIPPINES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 65. PHILIPPINES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 66. SINGAPORE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 67. SINGAPORE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 68. SINGAPORE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 69. SOUTH KOREA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 70. SOUTH KOREA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 71. SOUTH KOREA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 72. TAIWAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 73. TAIWAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 74. TAIWAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 75. THAILAND PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 76. THAILAND PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 77. THAILAND PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 78. VIETNAM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 79. VIETNAM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 80. VIETNAM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 83. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 85. DENMARK PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 86. DENMARK PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 87. DENMARK PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 88. EGYPT PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 89. EGYPT PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 90. EGYPT PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 91. FINLAND PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 92. FINLAND PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 93. FINLAND PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 94. FRANCE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 95. FRANCE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 96. FRANCE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 97. GERMANY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 98. GERMANY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 99. GERMANY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 100. ISRAEL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 101. ISRAEL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 102. ISRAEL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 103. ITALY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 104. ITALY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 105. ITALY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 106. NETHERLANDS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 107. NETHERLANDS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 108. NETHERLANDS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 109. NIGERIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 110. NIGERIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 111. NIGERIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 112. NORWAY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 113. NORWAY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 114. NORWAY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 115. POLAND PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 116. POLAND PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 117. POLAND PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 118. QATAR PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 119. QATAR PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 120. QATAR PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 121. RUSSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 122. RUSSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 123. RUSSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 124. SAUDI ARABIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 125. SAUDI ARABIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 126. SAUDI ARABIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 127. SOUTH AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 128. SOUTH AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 129. SOUTH AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 130. SPAIN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 131. SPAIN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 132. SPAIN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 133. SWEDEN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 134. SWEDEN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 135. SWEDEN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 136. SWITZERLAND PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 137. SWITZERLAND PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 138. SWITZERLAND PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 139. TURKEY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 140. TURKEY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 141. TURKEY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 142. UNITED ARAB EMIRATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 143. UNITED ARAB EMIRATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 144. UNITED ARAB EMIRATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 146. UNITED KINGDOM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 148. PARP INHIBITORS DRUG THERAPY MARKET SHARE, BY KEY PLAYER, 2023
TABLE 149. PARP INHIBITORS DRUG THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the PARP Inhibitors Drug Therapy Market, which are profiled in this report, include:
  • AbbVie Inc.
  • Artios Pharma Limited
  • AstraZeneca PLC
  • BeiGene, Inc.
  • Bristol-Myers Squibb Company
  • Clovis Oncology
  • GlaxoSmithKline PLC
  • IMPACT Therapeutics
  • Jeil Pharmaceuticals Co. Ltd.
  • Jiangsu Hengrui Pharmaceuticals Company Ltd.
  • Johnson & Johnson Services, Inc.
  • Karyopharm Therapeutics
  • Merck & Co., Inc.
  • Ono Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Repare Therapeutics, Inc.

Methodology

Loading
LOADING...

Table Information